Now showing items 1-2 of 2

  • Eslicarbazepine acetate response in intellectual disability population versus general population. 

    Allard, J; Lawthom, C; Henley, W; Mclean, B; Hudson, S; Tittensor, P; Rajakulendran, S; Ellawela, S; Pace, A; Shankar, R (Denmark, 2021-03)
    BACKGROUND: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic ...
  • The evidence for switching dibenzazepines in people with epilepsy. 

    Watkins, L; O'Dwyer, M; Oak, K; Lawthom, C; Maguire, M; Thomas, R; Shankar, R (Denmark, 2020-08)
    The dibenzazepines particularly carbamazepine are associated with known adverse effects (AEs) and drug to drug interactions. Eslicarbazepine acetate (ESL) is structurally distinct from other members of the dibenzazepine ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV